MX2014016121A - Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular. - Google Patents
Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.Info
- Publication number
- MX2014016121A MX2014016121A MX2014016121A MX2014016121A MX2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A MX 2014016121 A MX2014016121 A MX 2014016121A
- Authority
- MX
- Mexico
- Prior art keywords
- vascular endothelial
- endothelial function
- agent
- salt
- preventing deterioration
- Prior art date
Links
- 230000003845 vascular endothelial function Effects 0.000 title abstract 5
- 230000006866 deterioration Effects 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 3
- 229960002173 citrulline Drugs 0.000 abstract 3
- 235000013477 citrulline Nutrition 0.000 abstract 3
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe un agente de mejora de producción de NO, que comprende citrulina o una sal de la misma y serina o una sal de la misma como ingredientes activos; un agente para prevenir el deterioro de una función endotelial vascular o para mejorar la función endotelial vascular, que comprende citrulina o una sal de la misma y serina o una sal de la misma como ingredientes activos; y un agente profiláctico o benéfico para las afecciones asociadas con el deterioro de una función endotelial vascular, que comprende citrulina o una sal de la misma y serina o una sal de la misma como ingredientes activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012146572 | 2012-06-29 | ||
| PCT/JP2013/067767 WO2014003154A1 (ja) | 2012-06-29 | 2013-06-28 | 血管内皮機能低下の予防または改善剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014016121A true MX2014016121A (es) | 2015-09-21 |
Family
ID=49783288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014016121A MX2014016121A (es) | 2012-06-29 | 2013-06-28 | Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9833426B2 (es) |
| JP (1) | JP6193229B2 (es) |
| CA (1) | CA2877953A1 (es) |
| MX (1) | MX2014016121A (es) |
| WO (1) | WO2014003154A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5888574B1 (ja) * | 2015-07-02 | 2016-03-22 | 株式会社東洋新薬 | 血流改善剤 |
| NZ759534A (en) * | 2017-05-31 | 2025-10-31 | Kyowa Hakko Bio Co Ltd | Use of citrulline and glutathione to increase muscle mass |
| IT201700089011A1 (it) * | 2017-08-02 | 2019-02-02 | Kolinpharma S P A | Composizione per il trattamento e la prevenzione di disturbi della sfera sessuale maschile. |
| US20210283082A1 (en) * | 2018-06-07 | 2021-09-16 | National University Corporation Kanazawa University | Pharmaceutical composition for prevention or treatment of kidney damage |
| CN112469404A (zh) * | 2018-06-07 | 2021-03-09 | 国立大学法人金泽大学 | 肾损伤的预防或治疗用的药物组合物 |
| US10864207B2 (en) | 2019-01-02 | 2020-12-15 | Celagenex Research (India) Pvt. Ltd. | Method of treating endothelial dysfunction |
| PH12021551384A1 (en) | 2019-01-02 | 2022-03-28 | Celagenex Res India Pvt Ltd | Synergistic nutritional compositions for pain management |
| JP6838752B2 (ja) * | 2019-08-30 | 2021-03-03 | 株式会社東洋新薬 | 血流改善組成物 |
| CN118403044A (zh) * | 2024-05-20 | 2024-07-30 | 中国中医科学院中药研究所 | 氨基酸在制备治疗心肌损伤的药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3914585B2 (ja) * | 1995-10-19 | 2007-05-16 | イーエヌ大塚製薬株式会社 | マクロファージ一酸化窒素産生亢進剤 |
| JP3843298B2 (ja) | 2001-02-05 | 2006-11-08 | 国立大学法人 奈良先端科学技術大学院大学 | シトルリンを含有する活性酸素消去剤 |
| JP2002316929A (ja) * | 2001-04-18 | 2002-10-31 | Japan Science & Technology Corp | Ｌ−セリン又はグリシンからなる抗アポトーシス剤 |
| JP2006282648A (ja) * | 2005-03-31 | 2006-10-19 | Sunstar Inc | 美容食品用組成物 |
| JP5697835B2 (ja) * | 2005-12-05 | 2015-04-08 | 協和発酵バイオ株式会社 | 皮膚の乾燥予防または改善用経口剤 |
| JP2008222632A (ja) | 2007-03-13 | 2008-09-25 | Kyowa Hakko Kogyo Co Ltd | 関節炎改善剤 |
| JP2008273910A (ja) * | 2007-05-07 | 2008-11-13 | Kyowa Hakko Kogyo Co Ltd | 化粧料または皮膚外用剤 |
-
2013
- 2013-06-28 CA CA2877953A patent/CA2877953A1/en not_active Abandoned
- 2013-06-28 US US14/411,169 patent/US9833426B2/en active Active
- 2013-06-28 WO PCT/JP2013/067767 patent/WO2014003154A1/ja not_active Ceased
- 2013-06-28 MX MX2014016121A patent/MX2014016121A/es unknown
- 2013-06-28 JP JP2014522696A patent/JP6193229B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9833426B2 (en) | 2017-12-05 |
| CA2877953A1 (en) | 2014-01-03 |
| JP6193229B2 (ja) | 2017-09-06 |
| JPWO2014003154A1 (ja) | 2016-06-02 |
| WO2014003154A1 (ja) | 2014-01-03 |
| US20150141514A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014016121A (es) | Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular. | |
| EP3441468A3 (en) | Delivery methods and compositions for nuclease-mediated genome engineering | |
| PH12013500065A1 (en) | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof | |
| HK1208216A1 (en) | Drug-conjugates, conjugation methods, and uses thereof | |
| PH12013501524A1 (en) | Topical minocycline compositions and methods of using the same | |
| PH12012501755A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| MX384253B (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
| MX2013012542A (es) | Compuestos de amida y aplicacion farmaceutica para el mismo. | |
| MX352985B (es) | Formulaciones desinfectantes topicas y uso de las mismas. | |
| AU341603S (en) | Washer | |
| AU339376S (en) | Sterilizing case | |
| AU337887S (en) | Allsaw | |
| CA143394S (en) | Microwavable bag | |
| WO2013173789A3 (en) | Antisense oligonucleotide compositions | |
| PH12015500900A1 (en) | A stabilized pemetrexed formulation | |
| MX2013009252A (es) | Composiciones y procesos relacionados con los mismos plaguicidas. | |
| AR088099A1 (es) | Composicion anticaspa | |
| CA144465S (en) | Landscape edger | |
| MY161601A (en) | Films and compositions comprising the same | |
| MX350970B (es) | Métodos y composiciones para extender la vida útil en depósito de productos de plantas. | |
| CA144467S (en) | Landscape edger | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| AU337888S (en) | Allsaw | |
| CA145236S (en) | Pitcher | |
| WO2013095994A3 (en) | Transparent aqueous fragrance microemulsions |